Aquestive Therapeutics (AQST) EBT Margin (2017 - 2025)
Historic EBT Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 120.61%.
- Aquestive Therapeutics' EBT Margin fell 356200.0% to 120.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 524.42%, marking a year-over-year increase of 5840000.0%. This contributed to the annual value of 4380.06% for FY2024, which is 43649900.0% down from last year.
- Per Aquestive Therapeutics' latest filing, its EBT Margin stood at 120.61% for Q3 2025, which was down 356200.0% from 135.44% recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' EBT Margin ranged from a high of 72.46% in Q1 2023 and a low of 618.35% during Q2 2021
- In the last 5 years, Aquestive Therapeutics' EBT Margin had a median value of 109.36% in 2022 and averaged 128.5%.
- Per our database at Business Quant, Aquestive Therapeutics' EBT Margin skyrocketed by 4145800bps in 2022 and then tumbled by -1788900bps in 2024.
- Aquestive Therapeutics' EBT Margin (Quarter) stood at 261.28% in 2021, then skyrocketed by 56bps to 115.63% in 2022, then skyrocketed by 48bps to 60.65% in 2023, then soared by 163bps to 38.2% in 2024, then tumbled by -416bps to 120.61% in 2025.
- Its last three reported values are 120.61% in Q3 2025, 135.44% for Q2 2025, and 262.96% during Q1 2025.